The Renal Composite Benefit of Sodium Glucose Co-Transporter 2 Inhibitors Should Ideally Be Assessed Based on a Standardised Definition: A Meta-Analysis of Randomised Controlled Trials

(1) Background: Chronic kidney disease (CKD) is extremely common against the backdrop of type 2 diabetes (T2D), accounting for nearly 30–40% of cases. The conventional management strategy relie predominantly on metabolic control and the renin–angiotensin–aldosterone system (RAAS) blockage. In the la...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghosal, Samit, Ghosal, Shamita, Ghosal, Anuradha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10607004/
https://www.ncbi.nlm.nih.gov/pubmed/37892600
http://dx.doi.org/10.3390/jcm12206462

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10607004/
https://www.ncbi.nlm.nih.gov/pubmed/37892600
http://dx.doi.org/10.3390/jcm12206462

Ejemplares similares